Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Blood-pressure targets in comatose survivors of cardiac arrest

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Oxygen targets in comatose survivors of cardiac arrest

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Frostbite - Diagnosis and Therapy

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  • Stephen M Ansell
  • John Radford
  • Joseph M Connors
  • Monika Długosz-Danecka
  • Won-Seog Kim
  • Andrea Gallamini
  • Radhakrishnan Ramchandren
  • Jonathan W Friedberg
  • Ranjana Advani
  • Andrew M Evens
  • Piotr Smolewski
  • Kerry J Savage
  • Nancy L Bartlett
  • Hyeon-Seok Eom
  • Jeremy S Abramson
  • Cassie Dong
  • Frank Campana
  • Keenan Fenton
  • Markus Puhlmann
  • David J Straus
  • ECHELON-1 Study Group
  • Martin Hutchings
Vis graf over relationer

BACKGROUND: Five-year follow-up in a trial involving patients with previously untreated stage III or IV classic Hodgkin's lymphoma showed long-term progression-free survival benefits with first-line therapy with brentuximab vedotin, a CD30-directed antibody-drug conjugate, plus doxorubicin, vinblastine, and dacarbazine (A+AVD), as compared with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). A planned interim analysis indicated a potential benefit with regard to overall survival; data from a median of 6 years of follow-up are now available.

METHODS: We randomly assigned patients in a 1:1 ratio to receive up to six cycles of A+AVD or ABVD. The primary end point, modified progression-free survival, has been reported previously. The key secondary end point was overall survival in the intention-to-treat population. Safety was also assessed.

RESULTS: A total of 664 patients were assigned to receive A+AVD and 670 to receive ABVD. At a median follow-up of 73.0 months, 39 patients in the A+AVD group and 64 in the ABVD group had died (hazard ratio, 0.59; 95% confidence interval [CI], 0.40 to 0.88; P = 0.009). The 6-year overall survival estimates were 93.9% (95% CI, 91.6 to 95.5) in the A+AVD group and 89.4% (95% CI, 86.6 to 91.7) in the ABVD group. Progression-free survival was longer with A+AVD than with ABVD (hazard ratio for disease progression or death, 0.68; 95% CI, 0.53 to 0.86). Fewer patients in the A+AVD group than in the ABVD group received subsequent therapy, including transplantation, and fewer second cancers were reported with A+AVD (in 23 vs. 32 patients). Primary prophylaxis with granulocyte colony-stimulating factor was recommended after an increased incidence of febrile neutropenia was observed with A+AVD. More patients had peripheral neuropathy with A+AVD than with ABVD, but most patients in the two groups had resolution or amelioration of the event by the last follow-up.

CONCLUSIONS: Patients who received A+AVD for the treatment of stage III or IV Hodgkin's lymphoma had a survival advantage over those who received ABVD. (Funded by Takeda Development Center Americas and Seagen; ECHELON-1 ClinicalTrials.gov number, NCT01712490; EudraCT number, 2011-005450-60.).

OriginalsprogEngelsk
TidsskriftThe New England journal of medicine
Vol/bind387
Udgave nummer4
Sider (fra-til)310-320
Antal sider11
ISSN0028-4793
DOI
StatusUdgivet - 28 jul. 2022

Bibliografisk note

Copyright © 2022 Massachusetts Medical Society.

ID: 79392122